{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:18:28Z","timestamp":1790882308276,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Retinopathy of prematurity (ROP), a vascular disease characterized by abnormal vessel development in the retina, has become a primary cause of blindness in children around the world. ROP can be developed during two different phases: vessel loss and vessel proliferation. Once preterm infants with immature retinal vessel growth are exposed to high level of oxygen inside the incubator, vessel loss can occur. When infants are exposed to room air, they may experience the proliferation of vessels in the retina. Although multiple factors are reported to be involved in the pathogenesis of ROP, including vaso-endothelial growth factors (VEGFs) and hypoxia-inducible factors, the pathogenesis of ROP is not completely understood. Although laser therapy and pharmacologic agents, such as anti-VEGF agents, have been commonly used to treat ROP, the incidence of ROP is rapidly rising. Given that current therapies can be invasive and long-term effects are not fully known, the search for novel therapeutic targets with less destructive properties needs to be considered. Within the last decade, the field of noncoding RNA therapy has shown potential as next-generation therapy to treat diverse diseases. In this review, we introduce various noncoding RNAs regulating ROP and discuss their role as potential therapeutic targets in ROP.<\/jats:p>","DOI":"10.3389\/fphar.2022.1033341","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T09:02:56Z","timestamp":1666256576000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Noncoding RNAs as a novel approach to target retinopathy of prematurity"],"prefix":"10.3389","volume":"13","author":[{"given":"Hyunjong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaesub","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.5455\/medarh.2015.69.409-413","article-title":"Risk factors for retinopathy of prematurity in premature born children","volume":"69","author":"Alajbegovic-Halimic","year":"2015","journal-title":"Med. Arch."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.4155\/fmc.14.116","article-title":"miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents","volume":"6","author":"Baumann","year":"2014","journal-title":"Future Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-7435-1_15","article-title":"Construction of multi-potent MicroRNA sponge and its functional evaluation","volume":"1699","author":"Chang","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1161\/CIRCULATIONAHA.111.040337","article-title":"Wnt signaling mediates pathological vascular growth in proliferative retinopathy","volume":"124","author":"Chen","year":"2011","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1002\/jcp.29733","article-title":"Overexpression of miR-181a-5p inhibits retinal neovascularization through endocan and the ERK1\/2 signaling pathway","volume":"235","author":"Chen","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/iub.2307","article-title":"CircPDE4B inhibits retinal pathological angiogenesis via promoting degradation of HIF-1\u03b1 though targeting miR-181c","volume":"72","author":"Deng","year":"2020","journal-title":"IUBMB Life"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1101\/gr.132159.111","article-title":"The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression","volume":"22","author":"Derrien","year":"2012","journal-title":"Genome Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2020.00013","article-title":"MicroRNA-96 promotes vascular repair in oxygen-induced retinopathy-A novel uncovered vasoprotective function","volume":"11","author":"Desjarlais","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.4103\/1673-5374.306098","article-title":"Effects of long non-coding RNA myocardial infarction-associated transcript on retinal neovascularization in a newborn mouse model of oxygen-induced retinopathy","volume":"16","author":"Di","year":"2021","journal-title":"Neural Regen. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4103\/1673-5374.327358","article-title":"Maternally expressed gene 3 regulates retinal neovascularization in retinopathy of prematurity","volume":"17","author":"Di","year":"2022","journal-title":"Neural Regen. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrm.2015.2","article-title":"Beyond editing: Repurposing CRISPR-cas9 for precision genome regulation and interrogation","volume":"17","author":"Dominguez","year":"2016","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nmeth1079","article-title":"MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells","volume":"4","author":"Ebert","year":"2007","journal-title":"Nat. Methods"},{"key":"B16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrg3606","article-title":"Long non-coding RNAs: New players in cell differentiation and development","volume":"15","author":"Fatica","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"835771","DOI":"10.3389\/fphar.2022.835771","article-title":"Decoupling oxygen tension from retinal vascularization as a new perspective for management of retinopathy of prematurity. New opportunities from \u03b2-adrenoceptors","volume":"13","author":"Filippi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40942-018-0125-z","article-title":"Incidence and risk factors for retinopathy of prematurity: A retrospective cohort study","volume":"4","author":"Freitas","year":"2018","journal-title":"Int. J. Retina Vitr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"E2711","DOI":"10.3390\/jcm9092711","article-title":"Oxidative stress markers and the retinopathy of prematurity","volume":"9","author":"Graziosi","year":"2020","journal-title":"J. Clin. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fphar.2020.00276","article-title":"MicroRNA-18a-5p administration suppresses retinal neovascularization by targeting FGF1 and HIF1A","volume":"11","author":"Guan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","article-title":"Late-onset retinal findings and complications in untreated retinopathy of prematurity","volume":"4","author":"Hamad","year":"2020","journal-title":"Ophthalmol. Retina"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: A case series with paired-eye comparison","volume":"96","author":"Han","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","article-title":"Natural RNA circles function as efficient microRNA sponges","volume":"495","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e62589","DOI":"10.1371\/journal.pone.0062589","article-title":"Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer","volume":"8","author":"Hashimoto","year":"2013","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1161\/CIRCRESAHA.119.315856","article-title":"Preclinical and clinical development of noncoding RNA therapeutics for cardiovascular disease","volume":"126","author":"Huang","year":"2020","journal-title":"Circ. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/CIRCRESAHA.119.315938","article-title":"Noncoding RNAs in vascular diseases","volume":"126","author":"Jae","year":"2020","journal-title":"Circ. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1261\/rna.035667.112","article-title":"Circular RNAs are abundant, conserved, and associated with ALU repeats","volume":"19","author":"Jeck","year":"2013","journal-title":"Rna"},{"key":"B35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/CIRCRESAHA.116.308483","article-title":"SoxF transcription factors are positive feedback regulators of VEGF signaling","volume":"119","author":"Kim","year":"2016","journal-title":"Circ. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1101\/gad.270421.115","article-title":"Combinatorial control of Drosophila circular RNA expression by intronic repeats, hnRNPs, and SR proteins","volume":"29","author":"Kramer","year":"2015","journal-title":"Genes. Dev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e37601","DOI":"10.1371\/journal.pone.0037601","article-title":"Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis","volume":"7","author":"Kumar","year":"2012","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1261\/rna.047126.114","article-title":"Circular RNAs: Diversity of form and function","volume":"20","author":"Lasda","year":"2014","journal-title":"Rna"},{"key":"B40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40272-020-00433-z","article-title":"Ranibizumab: A review in retinopathy of prematurity","volume":"23","author":"Lee","year":"2021","journal-title":"Paediatr. Drugs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1161\/CIRCRESAHA.115.303142","article-title":"Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis","volume":"115","author":"Lee","year":"2014","journal-title":"Circ. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/nar\/gkv1206","article-title":"Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides","volume":"44","author":"Lennox","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3892\/mmr.2021.12577","article-title":"Inhibitory effect of miR1825p on retinal neovascularization by targeting angiogenin and BDNF","volume":"25","author":"Li","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.omtn.2020.08.032","article-title":"Identification of long noncoding RNAs involved in differentiation and survival of vascular smooth muscle cells","volume":"22","author":"Lim","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B45","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd4140","article-title":"MicroRNAs and other non-coding RNAs as targets for anticancer drug development","volume":"12","author":"Ling","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"911095","DOI":"10.3389\/fmed.2022.911095","article-title":"Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1, 627 eyes in China","volume":"9","author":"Linghu","year":"2022","journal-title":"Front. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"12163","DOI":"10.1073\/pnas.1508426112","article-title":"Endothelial microRNA-150 is an intrinsic suppressor of pathologic ocular neovascularization","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.omtn.2019.03.001","article-title":"MicroRNA-145 regulates pathological retinal angiogenesis by suppression of TMOD3","volume":"16","author":"Liu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.7150\/thno.19353","article-title":"Silencing of circular RNA-znf609 ameliorates vascular endothelial dysfunction","volume":"7","author":"Liu","year":"2017","journal-title":"Theranostics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1128\/mcb.23.1.14-25.2003","article-title":"Regulation of Notch1 and dll4 by vascular endothelial growth factor in arterial endothelial cells: Implications for modulating arteriogenesis and angiogenesis","volume":"23","author":"Liu","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/jcp.22942","article-title":"Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin \u03b1V\u03b23-FAK cascade","volume":"227","author":"Matsuda","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/onc.2014.2","article-title":"Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1\/2 pathway","volume":"34","author":"Miyake","year":"2015","journal-title":"Oncogene"},{"key":"B54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.addr.2013.12.008","article-title":"Liposomal siRNA nanocarriers for cancer therapy","volume":"66","author":"Ozpolat","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/eurheartj\/ehx165","article-title":"Non-coding RNAs in cardiovascular diseases: Diagnostic and therapeutic perspectives","volume":"39","author":"Poller","year":"2018","journal-title":"Eur. Heart J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1080\/15384047.2015.1046021","article-title":"miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications","volume":"16","author":"Ragusa","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"B57","first-page":"430","article-title":"MicroRNAs in vitreus humor from patients with ocular diseases","volume":"19","author":"Ragusa","year":"2013","journal-title":"Mol. Vis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"796143","DOI":"10.3389\/fped.2021.796143","article-title":"Vascular endothelial growth factor signaling in models of oxygen-induced retinopathy: Insights into mechanisms of pathology in retinopathy of prematurity","volume":"9","author":"Ramshekar","year":"2021","journal-title":"Front. Pediatr."},{"key":"B59","doi-asserted-by":"publisher","first-page":"107675","DOI":"10.1016\/j.pharmthera.2020.107675","article-title":"The roles of non-coding RNAs in vascular calcification and opportunities as therapeutic targets","volume":"218","author":"Ryu","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.omtn.2021.12.031","article-title":"Circular RNA circSmoc1-2 regulates vascular calcification by acting as a miR-874-3p sponge in vascular smooth muscle cells","volume":"27","author":"Ryu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.3390\/ijms23158529","article-title":"New aspects on the treatment of retinopathy of prematurity: Currently available therapies and emerging novel therapeutics","volume":"23","author":"Ryu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3928\/01913913-20200824-02","article-title":"Update on the use of anti-VEGF drugs in the treatment of retinopathy of prematurity","volume":"57","author":"Seery","year":"2020","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"B64","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1139\/bcb-2018-0304","article-title":"MicroRNA-34a attenuates VEGF-mediated retinal angiogenesis via targeting Notch1","volume":"97","author":"Shi","year":"2019","journal-title":"Biochem. Cell. Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"130","DOI":"10.22608\/APO.201853","article-title":"Pharmacotherapy and ROP: Going back to the basics","volume":"7","author":"Shulman","year":"2018","journal-title":"Asia. Pac. J. Ophthalmol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","article-title":"Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: A phase 1B, double-blind, randomised controlled trial","volume":"389","author":"Van Der Ree","year":"2017","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of microRNA therapeutics is coming of age","volume":"6","author":"Van Rooij","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"118299","DOI":"10.1016\/j.lfs.2020.118299","article-title":"Effect and mechanism of the long noncoding RNA MALAT1 on retinal neovascularization in retinopathy of prematurity","volume":"260","author":"Wang","year":"2020","journal-title":"Life Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1167\/iovs.63.1.37","article-title":"The long-noncoding RNA TUG1 regulates oxygen-induced retinal neovascularization in mice via MiR-299","volume":"63","author":"Wang","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B72","doi-asserted-by":"publisher","first-page":"112783","DOI":"10.1016\/j.yexcr.2021.112783","article-title":"Competing endogenous RNA network associated with oxygen-induced retinopathy: Expression of the network and identification of the MALAT1\/miR-124-3p\/EGR1 regulatory axis","volume":"408","author":"Xia","year":"2021","journal-title":"Exp. Cell. Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nmeth.1903","article-title":"Long-term, efficient inhibition of microRNA function in mice using rAAV vectors","volume":"9","author":"Xie","year":"2012","journal-title":"Nat. Methods"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.15252\/emmm.201404922","article-title":"Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis","volume":"7","author":"Yang","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1038\/s41380-021-01303-x","article-title":"Obesity-linked circular RNA circTshz2-2 regulates the neuronal cell cycle and spatial memory in the brain","volume":"26","author":"Yoon","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B76","doi-asserted-by":"publisher","first-page":"627774","DOI":"10.3389\/fmolb.2020.627774","article-title":"CRISPR-Cas13-Mediated knockdown of lncRNA-GACAT3 inhibited cell proliferation and motility, and induced apoptosis by increasing p21, bax, and E-cadherin expression in bladder cancer","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3892\/etm.2019.7819","article-title":"Oxygen-induced circRNA profiles and coregulatory networks in a retinopathy of prematurity mouse model","volume":"18","author":"Zhou","year":"2019","journal-title":"Exp. Ther. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1033341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T11:06:00Z","timestamp":1666695960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1033341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":77,"alternative-id":["10.3389\/fphar.2022.1033341"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1033341","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"1033341"}}